In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability

Dora Carrico, Junko Ohkanda, Howard Kendrick, Kohei Yokoyama, Michelle A. Blaskovich, Cynthia J. Bucher, Frederick S. Buckner, Wesley C. Van Voorhis, Debopam Chakrabarti, Simon L. Croft, Michael H. Gelb, Saïd M. Sebti, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

A series of ester derivatives of 17 with increased lipophilicity were synthesized and tested against P. falciparum in red blood cells, where the benzyl ester derivative 16 exhibited the best inhibition activity (ED 50 = 150 nM). Compound 16 showed in vivo antimalarial activity by 46.1% at a daily dose of 50 mg kg -1 using murine malaria models infected with Plasmodium berghei. A series of protein farnesyltransferase inhibitor ester prodrugs of FTI-2148 (17) were synthesized in order to evaluate the effects of ester structure modification on antimalarial activity and for further development of a farnesyltransferase inhibitor with in vivo activity. Evaluation against P. falciparum in red blood cells showed that all the investigated esters exhibited significant antimalarial activity, with the benzyl ester 16 showing the best inhibition (ED 50 = 150 nM). Additionally, compound 16 displayed in vivo activity and was found to suppress parasitemia by 46.1% at a dose of 50 mg kg -1 day -1 against Plasmodium berghei in mice. The enhanced inhibition potency of the esters is consistent with improved cell membrane permeability compared to that of the free acid. The results of this study suggest that protein farnesyltransferase is a valid antimalarial drug target and that the antimalarial activity of these compounds derives from a balance between the hydrophobic character and the size and conformation of the ester moiety.

Original languageEnglish (US)
Pages (from-to)6517-6526
Number of pages10
JournalBioorganic and Medicinal Chemistry
Volume12
Issue number24
DOIs
StatePublished - Dec 15 2004

Fingerprint

Peptidomimetics
Antimalarials
Permeability
Esters
Membranes
Plasmodium berghei
Blood
Erythrocytes
Cells
Cell Membrane Permeability
Farnesyltranstransferase
Derivatives
Parasitemia
p21(ras) farnesyl-protein transferase
In Vitro Techniques
Prodrugs
Cell membranes
Malaria
Conformations
Acids

Keywords

  • Ester prodrug
  • Peptidomimetic
  • Plasmodium falciparum
  • Protein farnesyltransferase

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. / Carrico, Dora; Ohkanda, Junko; Kendrick, Howard; Yokoyama, Kohei; Blaskovich, Michelle A.; Bucher, Cynthia J.; Buckner, Frederick S.; Van Voorhis, Wesley C.; Chakrabarti, Debopam; Croft, Simon L.; Gelb, Michael H.; Sebti, Saïd M.; Hamilton, Andrew.

In: Bioorganic and Medicinal Chemistry, Vol. 12, No. 24, 15.12.2004, p. 6517-6526.

Research output: Contribution to journalArticle

Carrico, D, Ohkanda, J, Kendrick, H, Yokoyama, K, Blaskovich, MA, Bucher, CJ, Buckner, FS, Van Voorhis, WC, Chakrabarti, D, Croft, SL, Gelb, MH, Sebti, SM & Hamilton, A 2004, 'In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability', Bioorganic and Medicinal Chemistry, vol. 12, no. 24, pp. 6517-6526. https://doi.org/10.1016/j.bmc.2004.09.020
Carrico, Dora ; Ohkanda, Junko ; Kendrick, Howard ; Yokoyama, Kohei ; Blaskovich, Michelle A. ; Bucher, Cynthia J. ; Buckner, Frederick S. ; Van Voorhis, Wesley C. ; Chakrabarti, Debopam ; Croft, Simon L. ; Gelb, Michael H. ; Sebti, Saïd M. ; Hamilton, Andrew. / In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. In: Bioorganic and Medicinal Chemistry. 2004 ; Vol. 12, No. 24. pp. 6517-6526.
@article{f149d5e6db66465aa8a0a4d7458d5c1c,
title = "In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability",
abstract = "A series of ester derivatives of 17 with increased lipophilicity were synthesized and tested against P. falciparum in red blood cells, where the benzyl ester derivative 16 exhibited the best inhibition activity (ED 50 = 150 nM). Compound 16 showed in vivo antimalarial activity by 46.1{\%} at a daily dose of 50 mg kg -1 using murine malaria models infected with Plasmodium berghei. A series of protein farnesyltransferase inhibitor ester prodrugs of FTI-2148 (17) were synthesized in order to evaluate the effects of ester structure modification on antimalarial activity and for further development of a farnesyltransferase inhibitor with in vivo activity. Evaluation against P. falciparum in red blood cells showed that all the investigated esters exhibited significant antimalarial activity, with the benzyl ester 16 showing the best inhibition (ED 50 = 150 nM). Additionally, compound 16 displayed in vivo activity and was found to suppress parasitemia by 46.1{\%} at a dose of 50 mg kg -1 day -1 against Plasmodium berghei in mice. The enhanced inhibition potency of the esters is consistent with improved cell membrane permeability compared to that of the free acid. The results of this study suggest that protein farnesyltransferase is a valid antimalarial drug target and that the antimalarial activity of these compounds derives from a balance between the hydrophobic character and the size and conformation of the ester moiety.",
keywords = "Ester prodrug, Peptidomimetic, Plasmodium falciparum, Protein farnesyltransferase",
author = "Dora Carrico and Junko Ohkanda and Howard Kendrick and Kohei Yokoyama and Blaskovich, {Michelle A.} and Bucher, {Cynthia J.} and Buckner, {Frederick S.} and {Van Voorhis}, {Wesley C.} and Debopam Chakrabarti and Croft, {Simon L.} and Gelb, {Michael H.} and Sebti, {Sa{\"i}d M.} and Andrew Hamilton",
year = "2004",
month = "12",
day = "15",
doi = "10.1016/j.bmc.2004.09.020",
language = "English (US)",
volume = "12",
pages = "6517--6526",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "24",

}

TY - JOUR

T1 - In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability

AU - Carrico, Dora

AU - Ohkanda, Junko

AU - Kendrick, Howard

AU - Yokoyama, Kohei

AU - Blaskovich, Michelle A.

AU - Bucher, Cynthia J.

AU - Buckner, Frederick S.

AU - Van Voorhis, Wesley C.

AU - Chakrabarti, Debopam

AU - Croft, Simon L.

AU - Gelb, Michael H.

AU - Sebti, Saïd M.

AU - Hamilton, Andrew

PY - 2004/12/15

Y1 - 2004/12/15

N2 - A series of ester derivatives of 17 with increased lipophilicity were synthesized and tested against P. falciparum in red blood cells, where the benzyl ester derivative 16 exhibited the best inhibition activity (ED 50 = 150 nM). Compound 16 showed in vivo antimalarial activity by 46.1% at a daily dose of 50 mg kg -1 using murine malaria models infected with Plasmodium berghei. A series of protein farnesyltransferase inhibitor ester prodrugs of FTI-2148 (17) were synthesized in order to evaluate the effects of ester structure modification on antimalarial activity and for further development of a farnesyltransferase inhibitor with in vivo activity. Evaluation against P. falciparum in red blood cells showed that all the investigated esters exhibited significant antimalarial activity, with the benzyl ester 16 showing the best inhibition (ED 50 = 150 nM). Additionally, compound 16 displayed in vivo activity and was found to suppress parasitemia by 46.1% at a dose of 50 mg kg -1 day -1 against Plasmodium berghei in mice. The enhanced inhibition potency of the esters is consistent with improved cell membrane permeability compared to that of the free acid. The results of this study suggest that protein farnesyltransferase is a valid antimalarial drug target and that the antimalarial activity of these compounds derives from a balance between the hydrophobic character and the size and conformation of the ester moiety.

AB - A series of ester derivatives of 17 with increased lipophilicity were synthesized and tested against P. falciparum in red blood cells, where the benzyl ester derivative 16 exhibited the best inhibition activity (ED 50 = 150 nM). Compound 16 showed in vivo antimalarial activity by 46.1% at a daily dose of 50 mg kg -1 using murine malaria models infected with Plasmodium berghei. A series of protein farnesyltransferase inhibitor ester prodrugs of FTI-2148 (17) were synthesized in order to evaluate the effects of ester structure modification on antimalarial activity and for further development of a farnesyltransferase inhibitor with in vivo activity. Evaluation against P. falciparum in red blood cells showed that all the investigated esters exhibited significant antimalarial activity, with the benzyl ester 16 showing the best inhibition (ED 50 = 150 nM). Additionally, compound 16 displayed in vivo activity and was found to suppress parasitemia by 46.1% at a dose of 50 mg kg -1 day -1 against Plasmodium berghei in mice. The enhanced inhibition potency of the esters is consistent with improved cell membrane permeability compared to that of the free acid. The results of this study suggest that protein farnesyltransferase is a valid antimalarial drug target and that the antimalarial activity of these compounds derives from a balance between the hydrophobic character and the size and conformation of the ester moiety.

KW - Ester prodrug

KW - Peptidomimetic

KW - Plasmodium falciparum

KW - Protein farnesyltransferase

UR - http://www.scopus.com/inward/record.url?scp=20844437245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844437245&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2004.09.020

DO - 10.1016/j.bmc.2004.09.020

M3 - Article

VL - 12

SP - 6517

EP - 6526

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 24

ER -